​
CURRICULUM VITAE
SANDRA ANN JACOBSON, MD
​
Research Associate Professor
University of Arizona College of Medicine-Phoenix
sandrajacobson@email.arizona.edu
EDUCATION AND TRAINING
-
Fellowship in Clinical Neurophysiology, UCLA Neuropsychiatric Institute, Los Angeles, CA (1990-92)
-
Residency in Psychiatry, UCLA Neuropsychiatric Institute (1988-91)
-
Internship in Internal Medicine, UH Integrated Medical Residency Program, Honolulu, HI (1987-88)
-
Doctor of Medicine, John A. Burns School of Medicine, University of Hawaii at Manoa (1983-87)
BOARD CERTIFICATIONS
-
American Board of Psychiatry & Neurology
Diplomate in Psychiatry (1993; lifetime) with Added Qualifications in Geriatric Psychiatry (1996, 2007), Psychosomatic Medicine (2006), and Clinical Neurophysiology (1996).
-
United Council for Neurologic Subspecialties
Diplomate in Neuropsychiatry/Behavioral Neurology (2015; renewed 2020)​.​
-
Neuroscience Education Institute
Master Psychopharmacology Program Certificate (2020)
​
ACADEMIC APPOINTMENTS
Jan 2007 - April 2015 Research Physician, Banner Research Institute, Sun City, AZ
Jan 2011 - present Research Associate Professor,
University of Arizona College of Medicine-Phoenix
Jan 2007-2011 Adjunct Professor of Psychology, Arizona State University, Phoenix
Dec 2003 – Oct 2006 Assistant Professor, Brown Medical School, Providence, RI
Nov 1993 – May 2003 Assistant Professor, Tufts University School of Medicine, Boston, MA
June 1992 – Oct 1993 Assistant Clinical Professor, UCLA School of Medicine, Los Angeles, CA
HOSPITAL APPOINTMENTS
Dec 2003 - Oct 2006 Director, Division of Consultation/Liaison Psychiatry,
The Miriam Hospital, Providence, RI
Aug 2003 – Dec 2003 Attending Psychiatrist, Taunton State Hospital,
Taunton, MA
June 2003 – July 2003 Attending Psychiatrist, Massachusetts General Hospital,
Boston, MA
Jan 2000 – May 2003 Director, Consultation/Liaison Psychiatry, New England Medical
Center, Boston, MA
July 2000 – Jan 2001 Attending Psychiatrist, Pratt 2 Inpatient Unit, New England
Medical Center, Boston, MA
Nov 1993 – May 2003 Attending Psychiatrist, New England Medical Center,
Boston, MA
April 1994 – Jan 2000 Director, Clinical EEG Laboratory, Lemuel Shattuck Hospital, Jamaica
Plain, MA
Nov 1993 – Jan 2000 Attending Psychiatrist, Geriatrics Service, Lemuel Shattuck Hospital,
Jamaica Plain, MA
Nov 1993 – Jan 2000 Chief of Clinical Neuroscience, Lemuel Shattuck Hospital, Jamaica
Plain, MA
June 1992 – Oct 1993 Staff Psychiatrist, UCLA/West Los Angeles VAMC
PEER-REVIEWED PUBLICATIONS
​
Original Articles
​
1.Leuchter AF, Jacobson SA. Quantitative measurement of brain electrical activity in delirium. International psychogeriatrics / IPA 1991;3:231-47.
2.Fogelson D, Jacobson S, Sternbach H. A retrospective study of valproate in a private psychiatric practice. Annals of Clinical Psychiatry 1991;3:315-320.
3.Lock J, Kleis B, Strouse T, Jacobson S, Yager J, Servis M. The role and function of residents' organizations in psychiatry education. Academic Psychiatry 1993;17:26-31.
4.Jacobson SA, Leuchter AF, Walter DO. Conventional and quantitative EEG in the diagnosis of delirium among the elderly. Journal of neurology, neurosurgery, and psychiatry 1993;56:153-8.
5.Jacobson SA, Leuchter AF, Walter DO, et al. Serial quantitative EEG among elderly subjects with delirium. Biological psychiatry 1993;34:135-40.
6.Ross BD, Jacobson SA, Villamil F, Korula J, Kreis R, Ernst T, Shonk T, Moats RA. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994;193:457-463.
7.Holzer JC, Jacobson SA, Folstein MF. Treating compulsive self-mutilation in a mentally retarded patient. The American journal of psychiatry 1996;153:133.
8.Jacobson S, Schreibman B. Behavioral and pharmacologic treatment of delirium. American Family Physician 1997;56:2005-2012.
9.Jacobson SA. Delirium in the elderly. The Psychiatric clinics of North America 1997;20:91-110.
10.Boutros NN, Jacobson SA, Campbell D. Role of the unquantified electroencephalography in psychiatric research. CNS spectrums 1999;4:60-3.
11.Jacobson S, Jerrier H. EEG in delirium. Seminars in Clinical Neuropsychiatry 2000;5:86-92.
12.Jacobson S. Psychopharmacology in hepatic and renal failure (a CME article). Psychiatric Times 2002 Nov XIX:65-69.
13.Jacobson SA, Folstein MF. Psychiatric perspectives on headache and facial pain. Otolaryngologic clinics of North America 2003;36:1187-200.
14.Jacobson SA, Dwyer PC, Machan JT, Carskadon MA. Quantitative analysis of rest-activity patterns in elderly postoperative patients with delirium: support for a theory of pathologic wakefulness. Journal of Clinical Sleep Medicine 2008;4:137-42.
15.Jacobson SA, Sabbagh MN. Donepezil: potential neuroprotective and disease-modifying effects. Expert Opinion on Drug Metabolism & Toxicology 2008;4:1363-9.
16.Ignatov I, Belden C, Jacobson S, et al. Possible Alzheimer's disease in an apolipoprotein E2 homozygote. Journal of Alzheimer's disease 2009;16:35-8.
17.Lue LF, Walker DG, Jacobson S, Sabbagh M. Receptor for advanced glycation end products: its role in Alzheimer’s disease and other neurological diseases. Future Neurology 2009; 4:167-177.
18.Cole L, Belden C, Jacobson S, Liebsack C, Myers K, Reninger C, Berk C, Sabbagh MN. Probable early-onset Alzheimer's disease in an apolipoprotein E2 homozygote. Dement Geriatr Cogn Disord 2010; 30:387-391.
19.Sabbagh MN, Malek-Ahmadi M, Kataria R, Belden CM, Connor DJ, Pearson C, Jacobson S, Yaari R, Singh U. The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment. J Alzheimers Dis 2010; 22:1015-1021.
20.Adler CH, Hentz JG, Shill HA, Sabbagh MN, Driver-Dunckley E, Evidente VG, Jacobson SA, Beach TG, Boeve B, Caviness JN. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism & Related Disorders 2011;17:456-8.
21.Damian AM, Jacobson SA, Hentz JG, et al. The Montreal Cognitive Assessment and the Mini-mental State Examination as screening instruments for cognitive impairment: item analyses and threshold scores. Dementia and Geriatric Cognitive Disorders 2011;31:126-31.
22.Jacobson SA, Sabbagh MN. Investigational drugs for the treatment of AD: what can we learn from negative trials? Alzheimer's Research & Therapy 2011;3:14.
23.Sabbagh MN, Fleisher A, Chen K, Rogers J, Berk C, Reiman E, Pontecorvo M, Mintun M, Skovronsky D, Jacobson SA, Sue LI, Liebsack C, Charney AS, Cole L, Belden C, Beach TG. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Archives of Neurology 2011;68:1461-6.
24.Cabral D, Beach TG, Vedders L, Sue LI, Jacobson S, Myers K, Sabbagh MN. Frequency of Alzheimer's disease pathology at autopsy in patients with clinical normal pressure hydrocephalus. Alzheimer's & Dementia 2011;7:509-13.
25.Malek-Ahmadi M, Davis K, Belden C, Laizure B, Jacobson S, Yaari R, Singh U, Sabbagh MN. Validation and diagnostic accuracy of the Alzheimer's questionnaire.2012;41:396-9.
26.Malek-Ahmadi M, Davis K, Belden CM, Jacobson S, Sabbagh MN. Informant-reported cognitive symptoms that predict amnestic mild cognitive impairment. BMC Geriatrics 2012;12:3.
27.Decourt B, Walker A, Gonzales A, Malek-Ahmadi M, Liebsack C, Davis KJ, Belden CM, Jacobson SA, Sabbagh MN. Can platelet BACE1 levels be used as a biomarker for Alzheimer'sdisease? Proof-of-concept study. Platelets 2013;24:235-8.
28.Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, Ahlskog JE, Caselli RJ, Jacobson S, Sabbagh M, Adler C, Woodruff B, Beach TG, Iranzo A, Gelpi E, Santamaria J, Tolosa E, Singer C, Mash DC, Luca C, Arnulf I, Duyckaerts C, Schenck CH, Mahowald MW, Dauvilliers Y, Graff-Radford NR, Wszolek ZK, Parisi JE, Dugger B, Murray ME, Dickson DW. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.Sleep Med 2013;14:754-62.
29.Maarouf CL, Beach TG, Adler CH, Malek-Ahmadi M, Kokjohn TA, Dugger BN, Walker DG, Shill HA, Jacobson SA, Sabbagh MN, Roher AE; Arizona Parkinson’s Disease Consortium. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomarker Insights 2013;8:19-28.
30.Jacobson S. Laboratory testing in the diagnosis of Alzheimer’s disease: an update. Psychiatric News Update 2013:2(40):1-3.
31.Jacobson S. Effects of pharmacokinetic and pharmacodynamic changes in the elderly (a CME article). Psychiatric Times 2013 Jan:26-29.
32.Sabbagh MN, Malek-Ahmadi M, Dugger BN, Lee K, Sue LI, Serrano G, Walker DG, Davis K, Jacobson SA, Beach TG. The influence of Apolipoprotein E genotype on regional pathology in Alzheimer’s disease. BMC Neurology 2013;13:44.
33.Kokjohn TA, Maarouf CL, Daugs ID, Hunter JM, Whiteside CM, Malek-Ahmadi M, Rodriguez E, Kalback W, Jacobson SA, Sabbagh MN, Beach TG, Roher AE. Neurochemical profile of dementia pugilistica. Journal of Neurotrauma 2013;30:981-97.
34.Malek-Ahmadi M, Kahlon V, Adler CA, Obradov A, Thind K, Shill HA, Sue LI, Caviness JN, Jacobson S, Sabbagh MN. Prevalence of hippocampal sclerosis in a clinicopathologically characterized cohort. Clin Exp Med Sci 2013;1:317-27.
35.Henderson-Smith A, Chow D, Meechoovet B, Aziz M, Jacobson SA, Shill HA, Sabbagh MN, Caviness JN, Adler CH, Driver-Dunckley ED, Beach TG, Yin H, Dunckley T.SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.PLoS One. 2013 Oct 30;8(10):e77711.
36.Roher AE, Maarouf CL, Malek-Ahmadi M, Wilson J, Kokjohn TA, Daugs ID, Whiteside CM, Kalback WM, Macias MP, Jacobson SA, Sabbagh MN, Ghetti B, Beach TG. Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations.Am J Neurodegener Dis. 2013;2:187-207.
37.Dugger BN, Adler CH, Shill HA, Caviness J, Jacobson S, Driver-Dunckley E, Beach TG; Arizona Parkinson's Disease Consortium. Concomitant pathologies among a spectrum of parkinsonian disorders.Parkinsonism & Related Disorders 2014;20:525-9.
38.Shill HA, Hentz JG, Jacobson SA, Belden C, Sabbagh MN, Beach TG, Driver-Dunckley E, Adler CH. Essential Tremor in the Elderly and Risk for Dementia.J Neurodegener Dis. 2014 328765.
39.Symanski C, Shill HA, Dugger B, Hentz JG, Adler CH, Jacobson SA, Driver-Dunckley E, Beach TG. Essential tremor is not associated with cerebellar Purkinje cell loss.Mov Disord. 2014;29:496-500.
40.Dugger BN, Hentz JG, Adler CH, Sabbagh MN, Shill HA, Jacobson S, Caviness JN, Belden C, Driver-Dunckley E, Davis KJ, Sue LI, Beach TG.Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers.J Neuropathol Exp Neurol. 2014;73:244-52.
41.Jacobson SA. Food interactions seen with many psychotropics.Psychiatric News. 2014; Vol 49 No. 13.
42.Adler CH, Beach TG, Hentz JG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Sue LI, Jacobson SA, Belden CM, Dugger BN. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study.Neurology. 2014 Jul 29;83(5):406-12.
43.Maarouf CL, Kokjohn TA, Walker DG, Whiteside CM, Kalback WM, Whetzel A, Sue LI, Serrano G, Jacobson SA, Sabbagh MN, Reiman EM, Beach TG, Roher AE. Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer's disease.PLoS One. 2014 Aug 28;9(8):e105784.
44.Jacobson SA, Simpson RG, Lubahn C, Hu C, Belden CM, Davis KJ, Nicholson LR, Long KE, Osredkar T, Lorton D. Characterization of fibromyalgia symptoms in patients 55-95 years old: a longitudinal study showing symptom persistence with suboptimal treatment. Aging Clin Exp Res
45.Jacobson SA, Morshed T, Dugger BN, Beach TG, Hentz JG, Adler CH, Shill HA, Sabbagh MN, Belden CM, Sue LI, Caviness JM, Hu C, and the Arizona Parkinson’s Disease Consortium. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations.Parkinsonism & Related Disorders 2014 Sep;20(9):1009-14.
46.Malek-Ahmadi M, Chen K, Davis K, Belden CM, Powell J, Jacobson, SA, Sabbagh MN. Sensitivity to change and prediction of global change for the Alzheimer's Questionnaire.Alzheimers Res Ther. 2015; Jan 8;7(1):1.
47.Dugger BN, Davis K, Malek-Ahmadi M, Hentz JG, Sandhu S, Beach TG, Adler CH, Caselli RJ, Johnson TA, Serrano GE, Shill HA, Belden C, Driver-Dunckley E, Caviness JN, Sue LI, Jacobson S, Powell J, Sabbagh MN. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurol. 2015 Aug 20;15:146.
48.Postuma RB, Adler CH, Dugger BN, Hentz JG, Shill HA, Driver-Dunckley E, Sabbagh MN, Jacobson SA, Belden CM, Sue LI, Serrano G, Beach TG. REM sleep behavior disorder and neuropathology in Parkinson's disease. Mov Disord. 2015 Sep;30(10):1413-7.
49.Sabbagh MN, Chen K, Rogers J, Fleisher AS, Liebsack C, Bandy D, Belden C, Protas H, Thiyyagura P, Liu X, Roontiva A, Luo J, Jacobson S, Malek-Ahmadi M, Powell J, Reiman EM.Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia. Alzheimer’s Dement. 2015 Aug;11(8):994-1004.
50.Budolfson K, Malek-Ahmadi M, Belden CM, Powell J, Davis K, Jacobson S, Sabbagh MN.Neuropsychological Correlates of the Alzheimer's Questionnaire. J Alzheimer’s Dis. 2015;46(2):389-97.
51.Beach TG, Adler CH, Sue LI, Serrano G, Shill HA, Walker DG, Lue L, Roher AE, Dugger BN, Maarouf C, Birdsill AC,Intorcia A, Saxon-Labelle M, Pullen J, Scroggins A, Filon J, Scott S, Hoffman B, Garcia A, Caviness JN, Hentz JG, Driver-Dunckley E, Jacobson SA, Davis KJ, Belden CM, Long KE, Malek-Ahmadi M, Powell JJ, Gale LD, Nicholson LR, Caselli RJ, Woodruff BK, Rapscak, SZ, Ahern GL, Shi J, Burke AD, Reiman EM, Sabbagh MN.Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology. 2015 Aug;35(4):354-89.
52.Filon JR, Intorcia AJ, Sue LI, Vazquez Arreola E, Wilson J, Davis KJ, Sabbagh MN, Belden CM, Caselli RJ, Adler CH, Woodruff BK, Rapscak SZ, Ahern GL, Burke AD, Jacobson S, Shill HA, Driver-Dunckley E, Chen K, Reiman EM, Beach TG, Serrano GE. Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition.J Neuropathol Exp Neurol. 2016 Jun 12. pii: nlw047. [Epub ahead of print]
53.Jacobson SA. Which metabolic panel for psychiatric practice: basic or comprehensive? Psychiatric News April 7, 2017; Vol 52 No 7.
​
​54.Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG. GBA mutations in Parkinson disease: earlier death but similar neuropathological features. 2017 Nov 24(11):1363-1368.
55.Savica R,Beach TG,Hentz JG,Sabbagh MN,Serrano GE,Sue LI,Dugger BN,Shill HA,Driver-Dunckley E, Caviness JN, Mehta SH, Jacobson SA,Belden CM,Davis KJ, Zamrini E, Shprecher DR,Adler CH. Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. Acta Neurol Scand. 2019 Jan;139(1):76-81.
56.Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Sabbagh MN, Serrano GE, Sue LI, Belden CM, Powell J, Jacobson SA, Zamrini E, Shprecher D, Davis KJ, Dugger BN, Hentz JG. Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging. J Neuropathol Exp Neurol. 2019 Oct 1;78(10):891-899.
57.Jacobson SA. Guidance on How to Diagnose and Treat Psychotropic Drug Reaction Known as DRESS. Psychiatric News September 2023; Vol 58 No 9, page 47.
58.Jacobson SA. Long Covid May Be Linked to Serotonin Levels. Psychiatric News January 2024; Vol 59 Issue 2.
​
59.Jacobson S. A Call to Action: Test Our Patients for Hepatitis C. Psychiatric News May 2024; Vol 59 Issue 5.
​
Books
-
Jacobson SA, Pies RW, Greenblatt DJ. Handbook of Geriatric Psychopharmacology. Washington, DC: American Psychiatric Publishing, Inc.; 2002.
-
Jacobson SA, Pies RW, Katz IR. Clinical Manual of Geriatric Psychopharmacology. Washington, DC: American Psychiatric Publishing, Inc., 2007.
-
Jacobson SA. Laboratory Medicine in Psychiatry and Behavioral Science. Washington, DC: American Psychiatric Publishing, Inc., 2012.
-
Jacobson SA. Clinical Manual of Geriatric Psychopharmacology, 2nd Ed. Washington, DC: American Psychiatric Publishing, Inc., 2014.
-
Jacobson SA. Clinical Laboratory Medicine for Mental Health Professionals. Arlington: American Psychiatric Association Publishing, 2017.
-
Jacobson SA. Laboratory Medicine in Psychiatry and Behavioral Science, 2nd Ed. Washington, DC: American Psychiatric Publishing, Inc., 2023.
​
Book Chapters
-
Jacobson SA, Leuchter AF. Delirium. In: Reichman WE, Katz PR, editors. Psychiatric Care in the Nursing Home. New York: Oxford University Press; 1996. p. 57-66.
-
Grossman H, Jacobson S, Folstein M. Neuroimaging and the normal elderly. In: Ames D, Chiu E, editors. Neuroimaging in the Psychiatry of Late Life. Cambridge: Cambridge University Press; 1997. p. 77-99.
-
Jacobson S. Delirium in the elderly. In: Martin RL, editor. Psychiatric Clinics of North America: Geriatric Psychiatry. Philadelphia: W.B. Saunders Company; 1997 20:91-110.
-
Jacobson S, Shader R. Delirium and Dementia. In: Shader RI, editor. Manual of Psychiatric Therapeutics. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p. 64-72.
-
Jacobson S, Folstein M. Psychiatric perspectives on headache and facial pain. In: Karmody CS, editor. Otolaryngologic Clinics of North America: Headache and Facial Pain. Philadelphia: Elsevier Science; 2003.
-
Liptzin B, Jacobson SA. Geriatric psychiatry: delirium. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 8th Ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
-
Salloway S, Harrington C, Jacobson S. Psychiatric evaluation of the neurological patient. In: Friedman J, Jeste D, editors. Psychiatry for Neurologists. Humana Press; 2005.
-
Jacobson S. Delirium and Dementia. In: Goldberg RJ, editor. Practical Guide to the Care of the Psychiatric Patient, 3rd Ed. Philadelphia: Elsevier Press; 2006.
-
Jacobson S. Alzheimer’s dementia. In: McNicoll L, editor. Geriatric Clinical Advisor: Instant Diagnosis and Treatment. Philadelphia: Elsevier Press; 2006.
-
Jacobson S, Shader R. Delirium and Dementia. In: Shader RI, editor. Manual of Psychiatric Therapeutics. 4th Ed. Philadelphia: Lippincott Williams & Wilkins 2009.
-
Liptzin B, Jacobson SA. Geriatric psychiatry: delirium. In: Sadock BJ, Sadock VA, and Ruiz P, editors. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. 9th Ed. Philadelphia: Lippincott Williams & Wilkins; 2009.
-
Jacobson, SA. Geriatric Psychopharmacology. In: Nair AK, and Sabbagh MN, editors. Geriatric Neurology. West Sussex: Wiley Blackwell; 2014.
-
Jacobson SA, Wilde EA. Clinical laboratory testing and neuroimaging in psychiatry. In Roberts L, editor. APA Textbook of Psychiatry, 7th Ed. Washington: APA Publishing; 2019.
​
Book Reviews
-
Jacobson S. Physical Consequences of Depression (Thakore JH, editor) [book review]. The New England Journal of Medicine 2003; 348:569-70.
-
Jacobson S. Bipolar Disorder in Later Life (Sajatovic M and Blow FC, editors) [book review]. Psychiatric Times December 2007; page 29.
-
Jacobson SA. The Johns Hopkins Atlas of Digital EEG (Gregory L. Krauss, MD, Robert S. Fisher, MD, PhD, and Peter W. Kaplan, MBBS, FRCP, Eds) [book review]. Journal of Neuropsychiatry and Clinical Neurosciences 2012; 24(1):115.
​
Letters
-
Jacobson SA, Leuchter AF. Delirium and quantitative EEG. Journal of Neurology, Neurosurgery and Psychiatry 1993;57:768.
-
Holzer J, Jacobson S, Folstein M. Combining clozapine and clomipramine in mental retardation with compulsive self-mutilatory behaviors. The American Journal of Psychiatry 1996;153:133.
​
Abstracts
1.Hammer RP, Yoshishige D, SA. Chronic cocaine exposure alters amygdalar and nigral opiate receptor binding in rats. Anatomical Record 1987;218:55-56A.
2.Hammer RP, Yoshishige D, SA. Effects of chronic cocaine on regional brain metabolism, dopamine and opiate receptor binding. Society for Neuroscience Abstracts 1987;13:85.
3.Hammer RP, SA. SuperBrain: a multimedia computer application for interdisciplinary neuroscience education. Society for Neuroscience Abstracts 1991;17:519.
4.Hammer RP, SA, Cooke ES, Foran S, Thomas WL. Atropine reduces neuronal activity in cortical, but not subcortical regions of rat brain. Biological Psychiatry 1996;39:589.
5. SA, Thomas WL, Cooke ES, Berezovskaya A, Hammer RP. Atropine selectively reduces metabolic activity in rat cerebral cortex. Biological Psychiatry 1996;39:510.
6. S, Berges A, Morales O, Ehrenberg B: EEG high frequency photic driving: association with delirium and dementia subgroups. Biological Psychiatry 1997;41:48S.
7.Jacobson S, Posever T, Berges A, Chelmow T: Abnormal EEG predicts outcome with clozapine treatment. Journal of Neuropsychiatry and Clinical Neurosciences 1998.
8. S, Dwyer P, Carskadon M: Delirium as a disorder of sleep homeostasis. American Association of Geriatric Psychiatry Meeting Abstracts 2007.
9. S: Evidence for inflammatory cytokines as the “final common pathway” in delirium pathogenesis. American Association of Geriatric Psychiatry Meeting Abstracts 2008.
10.Damian AM, SA, Belden C, Shill H, Sabbagh M, Vedders L, Adler CH: Analysis of the Montreal Cognitive Assessment (MoCA) and its individual domains versus the Mini-Mental State Examination in cognitively impaired versus cognitively normal patients as assessed by neuropsychological testing. American Academy of Neurology Meeting Abstracts 2010.
11.Adler CH, Hentz JG, Sabbagh MN, Connor DJ, Evidente VG, Driver-Dunckley ED, Tanner C, Kukull W, Vedders L, S, Caviness JN, Beach TG: Parkinson’s disease increases risk for mild cognitive impairment. American Academy of Neurology Meeting Abstracts 2010.
12.Derksen B, Malek-Ahmadi M, Belden C, Sabbagh M, S. Anosognosia for Memory Deficits in Amnestic MCI and Alzheimer's Disease. Arizona Alzheimer's Consortium Annual Meeting 2011.
13.Derksen B, Beach T, Goldstein I, Sabbagh M, Seltzer B, Sue L, and S. Frontal and Hippocampal Tangles and Plaque Density are Associated with Anosognosia in Alzheimer Disease. American Academy of Neurology Meeting Abstracts 2012.
​
14.Trisha Morshed, Sandra A. Jacobson, Thomas G. Beach, Charles H. Adler, Chengcheng Hue, Holly A. Shill, John N. Caviness, Christine M. Belden, Kathryn J. Davis, Lucia I. Sue, and Marwan N. Sabbagh, Arizona Parkinson’s Disease Consortium. Clinical and Neuropathological Correlates of Visual Hallucinations in Parkinsonism. American Association of Geriatric Psychiatry Meeting Abstracts 2013.
​
15.Trisha Morshed, Sandra A. Jacobson, Thomas G. Beach, Charles H. Adler, Chengcheng Hue, Holly A. Shill, John N. Caviness, Christine M. Belden, Kathryn J. Davis, Lucia I. Sue, and Marwan N. Sabbagh Arizona Parkinson’s Disease Consortium. Neuropathological Correlates of Visual Hallucinations in Parkinsonism. American Academy of Neurology Meeting Abstracts 2013.
​
INVITED PRESENTATIONS
-
Current Status of Diagnostic Procedures in Dementia, Advances in Clinical Psychopharmacology Conference, Tufts Department of Pharmacology and Experimental Therapeutics. Boston, MA 1995.
-
Dementia Diagnosis, Lahey Hitchcock Clinic, Department of Psychiatry and Behavioral Medicine Grand Rounds. Burlington, MA 1996.
-
Neuropsychiatric Disorders in the Elderly, Southwest Boston Geriatric Providers Group. Jamaica Plain, MA 1996.
-
Aggression in Alzheimer’s Disease. Newton-Wellesley Alzheimer’s Center. Wellesley, MA 1998.
-
Delirium in the Patient with Dementia, Newton-Wellesley Alzheimer’s Center Wellesley, MA 1999.
-
Treatment of Agitation in Dementia, Lahey Hitchcock Clinic Department of Psychiatry and Behavioral Medicine. Burlington, MA 2000.
-
Making Choices, Taking Risks (Keynote Speech), Massachusetts Association of Older Americans. Boston, MA 2000.
-
Update on Geriatric Psychopharmacology, Tufts New England Medical Center. Boston, MA 2001.
-
Subcortical Dementia, Southwest Boston Geriatric Providers Group. Jamaica Plain, MA 2001.
-
Dementia with Lewy Bodies, New England Geriatrics Annual Meeting. Springfield, MA 2002.
-
Dementia with Lewy Bodies, Quincy Medical Center Academic Conference. Quincy, MA 2002.
-
Dementia with Lewy Bodies, Lawrence Memorial Hospital Department of Psychiatry Grand Rounds. Medford, MA 2002.
-
Cholinesterase Inhibitors, Massachusetts Psychiatric Society. Wellesley, MA 2002.
-
Pharmacologic Treatment of Dementia, Annual Meeting of the Maine Psychiatric Association. Freeport, ME 2003.
-
Delirium, New England Medical Center Science Lecture Series. Boston, MA 2004.
-
Psychotropic Effects on Common Medical Conditions in the Elderly, Annual Geriatric Psychiatry Conference, The Miriam Hospital. Providence, RI 2004.
-
Decision-making Capacity, Annual Geriatric Psychiatry Conference, The Miriam Hospital. Warwick, RI 2005.
-
Pharmacologic Treatment of Dementia, Annual Meeting of the Maine Psychiatric Association. Portland, ME 2005.
19. Geriatric Psychiatry: New Ideas and New Practices for the 21st Century,
Symposium Chair and Speaker, Annual Meeting of the American Psychiatric Association.
Toronto, Canada 2006.
20. Treatment of Dementia with Behavioral Disturbance: If Not an Antipsychotic, then What?
Discussion Group Leader, Annual Meeting of the American Psychiatric Association, San Diego, CA 2007.
21. Delirium in the Elderly Patient, Geriatric Medicine Grand Rounds, St. Joseph’s Hospital.
Phoenix, AZ 2007.
22. Arizona Geriatrics Society Fall Symposium & Exhibition, Black Canyon Conference Center.
Phoenix, AZ 2007.
-
Overview of Delirium in the Elderly Patient
-
Medical Management of Delirium
-
Pharmacologic Management of Behavioral Disturbances in Dementia
23. Brain Fitness: A Talk with a Personal Trainer, Community Education Series, Sun Health
Research Institute. Sun City, AZ 2007.
24. CME Grand Rounds: Delirium in the Elderly Patient, Del E. Webb Hospital. Sun City West, AZ
2007.
25. CME Grand Rounds: Delirium in the Elderly Patient, Boswell Memorial Hospital. Sun City, AZ
2007.
26. The Blue Funk of Clinical Depression: How to Spot it, How to Stop it. Community
Education Series, Sun Health Research Institute, Sun City, AZ 2008.
27. Normal Aging versus Early Alzheimer’s Disease, Care Bears of Pebble Creek. Goodyear, AZ
2008.
28. Effective Interventions for the Delirious Patient. 1st Annual Invitational Geriatric Conference:
Healthy Outcomes in Aging, Hartford Center of Geriatric Nursing Excellence. Phoenix, AZ 2008.
29. Effective Interventions for the Delirious Patient. 1st Annual Invitational Geriatric Conference:
Healthy Outcomes in Aging, Hartford Center of Geriatric Nursing Excellence. Phoenix, AZ 2008.
30.University of Arizona College of Medicine Department of Psychiatry Grand Rounds: Delirium
Deconstructed, Arizona Health Sciences Center. Tucson, AZ 2008.
31. Arizona Health Care Association Annual Conference: Managing Delirium in Long-Term Care.
Glendale, AZ 2009.​
32. Alzheimer’s Association Desert Southwest Chapter: Understanding Alzheimer’s Disease.
Green Valley, AZ 2009.
33. Arizona Pharmacy Alliance/Health-System Academy Conference 2010: Focus on Neurology:
Advancements in Therapeutic Outcomes. Alzheimer’s Disease: Clinical Trials. Mesa, AZ 2010.
34. Banner MediSun Health Expo: Delirium: Acute Confusional State in Hospitalized Elders. Sun
City, AZ 2010.
35. Arizona Geriatrics Society Annual Meeting: Delirium. Phoenix, AZ 2010.
36. Solterra Senior Living/Northern Arizona Health Education Center: Delirium in the Elderly.
Show Low, AZ 2011.
37. Alzheimer’s Association Annual Mayor’s Caregiver Conference, Keynote Speech: Clinging,
Hoarding, Repeating Questions, and More…Alzheimer’s Disease Behaviors that Drive Us Crazy, and What to Do About Them. Tucson, AZ 2011.
38. Sun Health Foundation Springfest: Brain Fitness. Sun City West, AZ 2011.
39. Royal Oaks Educational Forum: Brain Fitness. Sun City, AZ 2011.
40. Banner MediSun Health Expo: Brain Fitness. Sun City West, AZ 2011.
41. Sun Health Senior Living: Brain Fitness, Surprise, AZ 2011.
42. Sun Health Foundation Springfest: Sleepless in Sun City (Insomnia), Sun City, AZ 2012.
43. Banner MediSun Health Expo: Brain Fitness. Sun City West, AZ 2012.
44. Meet the Author Workshop: Laboratory Medicine in Psychiatry and Behavioral Science.
American Psychiatric Association Annual Meeting, Philadelphia, PA 2012.
45. Meet the Author Session: Advanced Geriatric Psychopharmacology: Focus on the Psychiatry
Consultation/Liaison Service. American Psychiatric Association Annual Meeting, San Francisco, CA 2013.
46. Chair, Advances in Geriatric Psychopharmacology Session, American Psychiatric Association
Annual Meeting, San Francisco, CA 2013.
47. Annual Education Conference, Alzheimer’s Association Desert Southwest Chapter: Dementia
and Memory Loss. East Valley Institute of Technology, Mesa, AZ 2014.
48. Arizona Assisted Living Foundation Annual Conference: Diet for a Healthy Brain, Fountain
Hills, AZ 2014.
49. Meet the Author Session: Advanced Geriatric Psychopharmacology II: Focus on the
Psychiatry Consultation/Liaison Service. American Psychiatric Association Annual Meeting, New York,
NY 2014.
50. Chair, Advances in Geriatric Psychiatry Session, American Psychiatric Association Annual
Meeting, New York, NY 2014.
51. Geriatric Psychopharmacology Update, Psychopharmacology Institute, online CME course 2017.
52. Laboratory Testing in the Practice of Psychopharmacology, Psychopharmacology Institute,
online CME course 2019.
​
​
UNIVERSITY AND HOSPITAL TEACHING
Medical Students Year 1
2007-2008 Lecturer in Clinical Neurosciences and Psychopharmacology
Participant in Learning Community
University of Arizona/ASU College of Medicine – Phoenix
1998-2001 Course Developer and Director, Geriatrics Mini-Course
Tufts University School of Medicine
1995-2001 Lecturer, Growth & Development Course: Late Life
Lecturer, Interviewing Course (Elderly Patients)
Tufts University School of Medicine, Boston, MA
Medical Students Year 2
1998-2002 Psychopathology Course Co-Director
Tufts University School of Medicine
1995-2003 Lecturer, Psychopathology Course: Cognitive Disorders, Somatoform Disorders
Tufts University School of Medicine
1998-2005 Medical Pharmacology Conference Group Leader: Psychopharmacology
Tufts University School of Medicine
Medical Students Year 3
2000-2007 Director, Psychiatry Core Clerkship
Tufts University School of Medicine – New England Medical Center
Brown Medical School – The Miriam Hospital, Providence, RI
Medical Students Year 4
2000-2006 Director, Elective and Subinternship Rotations in Consultation/Liaison Psychiatry
Tufts University School of Medicine
Brown Medical School
2007-2008 Director, Elective and Subinternship Rotations in Geriatric Neuropsychiatry
University of Arizona School of Medicine
Medical Students: All Years
Scholarly Project Advisor: University of Arizona School of Medicine
Anne Damian Class of 2012
Rachel Simpson Class of 2013
Brenna Derksen Class of 2014
Trisha Morshed Class of 2015
Psychiatry Residency Training
1993-2006 Director, Required and Elective Geriatric Psychiatry Rotations, PGY2-4
Tufts University School of Medicine and Brown Medical School
2004-2006 Lecturer, Department of Psychiatry and Behavioral Sciences, Brown Medical School
Delirium, Catatonia and Related Disorders
2004-2006 Lecturer, Internal Medicine Program, Brown Medical School-
The Miriam Hospital
-
Depression and Antidepressants
-
Anxiety Disorders and Anxiolytics,
-
Delirium
-
Delirium Tremens
-
Somatoform Disorders
-
Capacity to Consent
Psychology Internship Training
2003-2006 Director, Core Clerkship in Medical Psychology
Department of Psychology, Brown University
2004-2006 Behavioral Medicine Seminar Speaker: Psychopharmacology
Department of
Psychology, Brown University
2007-2008 Clinical Site Director
Arizona State University Clinical Psychology Training Program
​
Geriatric Psychiatry Fellowship Training
2001-2003 Director, Geriatric Psychiatry Fellowship Training Program
Tufts University School of Medicine
2003-2006 Director, Rotation in Geriatric Consultation/Liaison Psychiatry
Brown Medical School
​
Geriatric Medicine Fellowship Training
2004-2006 Seminar Speaker, Brown Medical School Geriatrics Program.
2007-2008 Core Faculty, Sun Health/St. Joseph’s Geriatric Fellowship Program, Sun City, AZ
RESEARCH ACTIVITIES
Site Sub-Investigator, Arizona Alzheimer’s Disease Core Center (Eric Reiman, PI).
Ongoing role in the physical, neurological, and cognitive evaluation of Alzheimer’s disease and control patients. A core participant in consensus conferences and educational forums.
Site Sub-Investigator, Arizona Parkinson’s Disease Consortium and the Michael J. Fox Foundation for Parkinson’s Research (Charles Adler and Thomas Beach, PIs). Ongoing role in the physical, neurological, and cognitive evaluation of Parkinson’s disease and control patients. A core participant in consensus conferences and educational forums.
Site Sub-Investigator, Seattle Institute for Biomedical and Clinical Research, Prevention of Alzheimer’s Disease and Cognitive Decline. Physical, neurological, and cognitive evaluation of patients from the original ADAPT study.
Site Sub-Investigator, Study on Thalidomide as BACE1 inhibitor in Alzheimer’s disease (Marwan Sabbagh, PI). Physical, neurological, and cognitive evaluation of patients with Alzheimer’s disease.
Sponsored Clinical Trials (Site Sub-Investigator)
A phase IIa, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose, safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity trial of AAB-001 (ELN116727) in patients with mild to moderate Alzheimer’s disease. Elan Pharmaceuticals.
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's disease who are apolipoprotein e4 carriers. Elan Pharmaceuticals.
A phase 1, multicenter, randomized, blinded, single ascending dose, safety, and tolerability trial of ACC-001 (QS21) in patients with mild to moderate AD. Elan Pharmaceuticals.
A double-blind, parallel-group comparison of 23 mg donepezil sustained release
(SR) to 10 mg donepezil immediate release (IR) in patients with moderate to severe
Alzheimer's disease. Eisai Medical Research Inc.
A global phase 3, double-blind, placebo-controlled safety and efficacy study of oral
Dimebon in patients with mild-to-moderate Alzheimer's disease (CONNECTION Study). Medivation.
A phase II, randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral ELND005 (AZD-103) in Alzheimer's disease. Elan Pharmaceuticals.
A phase III study of the effect of γ-secretase inhibition on the progression of Alzheimer's disease: LY450139 versus placebo. Eli Lilly and Company.
An Open-Label Extension Study of Combination Therapy with Dimebon and Donepezil in Patients with Alzheimer’s Disease (DIM13 Study). Medivation.
An Open Label, Parallel Group, Multicenter Study Evaluating the Safety and Imaging Characteristics of 18F-AV-45 in Healthy Volunteers, Patients with Mild Cognitive Impairment, and Patients with Alzheimer’s Disease. Avid Radiopharmaceuticals.
An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 PET for Detection/Exclusion of Cerebral Amyloid Beta in Patients with Probable Alzheimer’s Disease Compared to Healthy Volunteers. Bayer Healthcare.
An Open-label, Non-randomized Study to Evaluate the Efficacy and Safety of BAY 94-9172 PET Imaging for Detection/Exclusion of Cerebral b-amyloid when Compared to Postmortem Histopathology. Bayer Healthcare.
A Principal Open-label Study to Assess the Prognostic Usefulness of 18Flutemetamol Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzheimer’s Disease. GE Healthcare.
A Principal Open-label Study to Compare the Brain Uptake of 18Flutemetamol with Brain Amyloid Levels Determined Post-mortem. GE Healthcare.
A Double-blind, Placebo-controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects with Mild to Moderate Alzheimer’s Disease.
A Phase 2, Multicenter, 24-Month, Randomized, Placebo-Controlled, Parallel-Group Amyloid Positron Emission Tomography (PET) and Safety Trial of ACC-001 and QS-21 Adjuvant in Subjects with Early Alzheimer’s Disease. Pfizer.
Deep Brain Stimulation Trial in Alzheimer’s disease. Functional Neuromodulation.
​
Study of Wrist Actigraphby in Hospitalized Patients with Delirium versus Controls. The Miriam Hospital, Brown School of Medicine, 2005-2006.
​
Study of Proton MR Spectroscopy in Subclinical Hepatic Encephalopathy. Imaging Laboratory of Brian Ross, Pasadena, CA, 1993-94.
​
Studies of Quantitative EEG and Serial Quantitative EEG in Delirium. Laboratory of Andrew Leuchter, UCLA Neuropsychiatric Institute, 1990-93.
​
​
November, 2023